Cargando…
Phage therapy: Targeting intestinal bacterial microbiota for the treatment of liver diseases
Phage therapy has been overshadowed by antibiotics for decades. However, it is being revisited as a powerful approach against antimicrobial-resistant bacteria. As bacterial microbiota have been mechanistically linked to gastrointestinal and liver diseases, precise editing of the gut microbiota via t...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10641246/ https://www.ncbi.nlm.nih.gov/pubmed/37965159 http://dx.doi.org/10.1016/j.jhepr.2023.100909 |
_version_ | 1785146734202060800 |
---|---|
author | Fujiki, Jumpei Schnabl, Bernd |
author_facet | Fujiki, Jumpei Schnabl, Bernd |
author_sort | Fujiki, Jumpei |
collection | PubMed |
description | Phage therapy has been overshadowed by antibiotics for decades. However, it is being revisited as a powerful approach against antimicrobial-resistant bacteria. As bacterial microbiota have been mechanistically linked to gastrointestinal and liver diseases, precise editing of the gut microbiota via the selective bactericidal action of phages has prompted renewed interest in phage therapy. In this review, we summarise the basic virological properties of phages and the latest findings on the composition of the intestinal phageome and the changes associated with liver diseases. We also review preclinical and clinical studies assessing phage therapy for the treatment of gastrointestinal and liver diseases, as well as future prospects and challenges. |
format | Online Article Text |
id | pubmed-10641246 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-106412462023-11-14 Phage therapy: Targeting intestinal bacterial microbiota for the treatment of liver diseases Fujiki, Jumpei Schnabl, Bernd JHEP Rep Review Phage therapy has been overshadowed by antibiotics for decades. However, it is being revisited as a powerful approach against antimicrobial-resistant bacteria. As bacterial microbiota have been mechanistically linked to gastrointestinal and liver diseases, precise editing of the gut microbiota via the selective bactericidal action of phages has prompted renewed interest in phage therapy. In this review, we summarise the basic virological properties of phages and the latest findings on the composition of the intestinal phageome and the changes associated with liver diseases. We also review preclinical and clinical studies assessing phage therapy for the treatment of gastrointestinal and liver diseases, as well as future prospects and challenges. Elsevier 2023-09-23 /pmc/articles/PMC10641246/ /pubmed/37965159 http://dx.doi.org/10.1016/j.jhepr.2023.100909 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Review Fujiki, Jumpei Schnabl, Bernd Phage therapy: Targeting intestinal bacterial microbiota for the treatment of liver diseases |
title | Phage therapy: Targeting intestinal bacterial microbiota for the treatment of liver diseases |
title_full | Phage therapy: Targeting intestinal bacterial microbiota for the treatment of liver diseases |
title_fullStr | Phage therapy: Targeting intestinal bacterial microbiota for the treatment of liver diseases |
title_full_unstemmed | Phage therapy: Targeting intestinal bacterial microbiota for the treatment of liver diseases |
title_short | Phage therapy: Targeting intestinal bacterial microbiota for the treatment of liver diseases |
title_sort | phage therapy: targeting intestinal bacterial microbiota for the treatment of liver diseases |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10641246/ https://www.ncbi.nlm.nih.gov/pubmed/37965159 http://dx.doi.org/10.1016/j.jhepr.2023.100909 |
work_keys_str_mv | AT fujikijumpei phagetherapytargetingintestinalbacterialmicrobiotaforthetreatmentofliverdiseases AT schnablbernd phagetherapytargetingintestinalbacterialmicrobiotaforthetreatmentofliverdiseases |